» Articles » PMID: 12390950

Iron Therapy, Advanced Oxidation Protein Products, and Carotid Artery Intima-media Thickness in End-stage Renal Disease

Overview
Journal Circulation
Date 2002 Oct 23
PMID 12390950
Citations 82
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Increased common carotid artery intima-media thickness (CCA-IMT) is a marker of early atherosclerosis. Low-grade inflammation is associated with the pathogenesis of atherosclerosis. Low-grade inflammation and increased CCA-IMT are observed in end-stage renal disease (ESRD). Oxidative stress is involved in uremia-related inflammation. Advanced oxidation protein products (AOPP) are markers of oxidant-mediated protein damage in ESRD. Intravenous iron given to patients on hemodialysis (HD) might induce oxidative stress. We investigated the relationships between AOPP, iron therapy, and CCA-IMT in stable HD patients.

Methods And Results: Plasma AOPP and blood chemistry, including iron status, were analyzed in a cohort of 79 ESRD patients on HD. Measurements of CCA-IMT and CCA diameter, as assessed by B-mode ultrasonography, were obtained in 60 patients. AOPP levels were elevated in ESRD patients, and in univariate (r=0.42, P<0.0001) and multivariate analyses (r=0.38, P<0.001), they correlated with serum ferritin and with the intravenous iron dose received during the 12 months preceding the study (ferritin, P<0001; AOPP, P<0.01). Univariate and multivariate analyses identified the AOPP concentration as being significantly associated with CCA-IMT (P=0.0197) and CCA wall-to-lumen ratio (r=0.560, P<0.0001). Independently of AOPP concentration, cumulative iron dose was positively related to CCA-IMT (P=0.015) in patients <60 years.

Conclusion: In ESRD patients, CCA-IMT and CCA wall-to-lumen ratio were associated with plasma AOPP, serum ferritin, and the annual intravenous iron dose administered. These findings support the concept of a role of oxidative stress in the early atherosclerosis of ESRD patients, which may be increased by the usually recommended doses of intravenous iron.

Citing Articles

Relationship between Compound α-Ketoacid and Microinflammation in Patients with Chronic Kidney Disease.

Chen Z, Lin Y, Wang J, Yao K, Xie Y, Chen X Curr Pharm Des. 2024; 30(8):589-596.

PMID: 38477209 DOI: 10.2174/0113816128291248240131102709.


Association of Estimated Total Body Iron with All-Cause Mortality in Japanese Hemodialysis Patients: The Miyazaki Dialysis Cohort Study.

Toida T, Sato Y, Komatsu H, Fujimoto S Nutrients. 2023; 15(21).

PMID: 37960311 PMC: 10649821. DOI: 10.3390/nu15214658.


Low-Dose Oral Iron Replacement Therapy Is Effective for Many Japanese Hemodialysis Patients: A Retrospective Observational Study.

Ogawa C, Tsuchiya K, Kanemitsu M, Maeda K Nutrients. 2023; 15(1).

PMID: 36615783 PMC: 9824721. DOI: 10.3390/nu15010125.


Markers of Oxidative Stress, Inflammation and Endothelial Function following High-Dose Intravenous Iron in Patients with Non-Dialysis-Dependent Chronic Kidney Disease-A Pooled Analysis.

Kassianides X, White S, Bhandari S Int J Mol Sci. 2022; 23(24).

PMID: 36555659 PMC: 9787941. DOI: 10.3390/ijms232416016.


Evaluation of Oxidative Status in Elderly Patients with Multiple Cerebral Infarctions and Multiple Chronic Total Coronary Occlusions.

Li X, Guo D, Hu Y, Chen Y Dis Markers. 2022; 2022:2083990.

PMID: 35801004 PMC: 9256345. DOI: 10.1155/2022/2083990.